FOR IMMEDIATE RELEASE
ULTRAGREEN.AI STRENGTHENS FLUORESCENCE TECHNOLOGY LEADERSHIP THROUGH STRATEGIC ACQUISITION OF PERFUSION TECH APS.
Singapore-Based UltraGreen.ai Accelerates Global Adoption of Quantification in Fluorescence-Guided Surgery through strategic acquisition
Singapore, June 17, 2025 — UltraGreen.ai (UltraGreen), a Singapore-headquartered leader in surgical imaging technology, today announced the acquisition of Perfusion Tech, a clinical software innovator focused on real-time perfusion quantification during surgical procedures. This strategic acquisition positions UltraGreen at the forefront of fluorescence-guided surgery (FGS) and opens a broader commercial pathway into perfusion assessment.
By combining UltraGreen’s fluorescence imaging products, its advanced data and imaging infrastructure with Perfusion Tech’s validated clinical quantification engine, this creates a comprehensive surgical intelligence platform that transforms intraoperative imaging – delivering standardised, objective and reproducible perfusion assessments that drive safer, more precise surgical outcomes.
“This acquisition marks a significant milestone in the evolution not only for fluorescence-guided surgery but for how we think about tissue viability across multiple clinical domains,” said Ravi Sajwan, Co-CEO of UltraGreen.ai. “With Perfusion Tech’s platform, we are unlocking a new layer of insights—bringing scalable, quantitative intelligence to procedures where precision is critical, from colorectal and reconstructive surgery to the diabetic ulcer market and beyond. We’re creating technology that enables surgeons to make more precise, data-driven decisions during critical procedures, which directly translates to better patient outcomes and more efficient healthcare delivery.”
